ArticleJournal for immunotherapy of cancer2024

Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.

Tessa Gargett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.